title: [Reduction of intra- and post-operative bleeding after treatment with a peptide fraction derived from bovine factor VIII].
abstract: The most common post-operative complication of adenotonsillectomy is an excessive bleeding. This problem persists although the laboratory investigations may exclude hemocoagulative anomalies and the anamnesis is able to show the presence or not of genetic factors or constitutional disease. Even if the surgical operation is performed in a technical proper way, the risk of bleeding is still present. Therefore we have valued new prospects of application in pediatric O.R.L. of a peptide fraction from bovine factor VIII. This compound has proved to be able to reduce the bleeding time. We valued the action of this drug compared with that of tranexamic acid and in comparison with the results obtained before treatment. Furthermore, we have also investigated the possibility of influence of this drug on haemocoagulative parameters and we have concluded that the drug does not show any effect on them.
authors.affiliation: Divisione di Otorinolaringologia, Istituto G. Gaslini, Genova, Italia.
authors.forename: V
authors.initials: V
authors.lastname: Tarantino
authors.forename: M
authors.initials: M
authors.lastname: Cingolani
authors.forename: L
authors.initials: L
authors.lastname: Benzi
authors.forename: P
authors.initials: P
authors.lastname: Fortini
mesh_terms: D000233:Adenoidectomy; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004341:Drug Evaluation; D005169:Factor VIII / Q000627:therapeutic use*; D005260:Female; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D008297:Male; D014068:Tonsillectomy; D014148:Tranexamic Acid / Q000627:therapeutic use*
chemical_list: D003509:Cyclohexanecarboxylic Acids; D014148:Tranexamic Acid; D005169:Factor VIII
vernacular_title: Diminuzione del sanguinamento intra e post-operatorio dopo trattamento con una frazione peptidica derivata dal fattore VIII bovino.